Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery

References

• Prum BE, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern® guidelines. Ophthalmology. 2016;123(1):P41–P111. doi:10.1016/j.ophtha.2015.10.053
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279. doi:10.1001/archopht.120.10.1268
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48–56. doi:10.1001/archopht.121.1.48
   PubMedGoogle Scholar
• The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440. doi:10.1016/S0002-9394(00)00538-9
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4):487–497. doi:10.1016/S0002-9394(98)00223-2
   PubMed Web of Science ®Google Scholar
• Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295–1304. doi:10.1016/S0140-6736(14)62111-5
   PubMed Web of Science ®Google Scholar
• Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol. 2013;131(12):1573–1582. doi:10.1001/jamaophthalmol.2013.5059
   PubMed Web of Science ®Google Scholar
• Kaplowitz K, Schuman JS, Loewen NA. Techniques and outcomes of minimally invasive trabecular ablation and bypass surgery. Br J Ophthalmol. 2014;98(5):579–585. doi:10.1136/bjophthalmol-2013-304546
   PubMed Web of Science ®Google Scholar
• El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12:4–8. doi:10.1097/00055735-200102000-00002
   PubMed Web of Science ®Google Scholar
• Porela-Tiihonen S, Kaarniranta K, Kokki M, Purhonen S, Kokki H. A prospective study on postoperative pain after cataract surgery. Clin Ophthalmol. 2013;7:1429–1435.
   PubMedGoogle Scholar
• Lundberg B, Jonsson M, Behndig A. Postoperative corneal swelling correlates strongly to corneal endothelial cell loss after phacoemulsification cataract surgery. Am J Ophthalmol. 2005;139(6):1035–1041. doi:10.1016/j.ajo.2004.12.080
   PubMed Web of Science ®Google Scholar
• Chuck RS, Jacobs DS, Lee JK, et al. American Academy of Ophthalmology Preferred Practice Pattern Refractive Management/Intervention Panel. Refractive errors & refractive surgery preferred practice pattern®. Ophthalmology. 2018;125(1):P1–P104. doi:10.1016/j.ophtha.2017.10.003
   Web of Science ®Google Scholar
• Olson RJ, Braga-Mele R, Chen SH, et al. Cataract in the adult eye preferred practice pattern®. Ophthalmology. 2017;124(2):P1–P119. doi:10.1016/j.ophtha.2016.09.027
   PubMed Web of Science ®Google Scholar
• Yildirim Y, Kar T, Duzgun E, Sagdic SK, Ayata A, Unal MH. Evaluation of the long-term results of trabectome surgery. Int Ophthalmol. 2016;36(5):719–726. doi:10.1007/s10792-016-0190-y
   Web of Science ®Google Scholar
• Khaimi MA. Canaloplasty: A minimally invasive and maximally effective glaucoma treatment. J Ophthalmol. 2015;2015:485056. doi:10.1155/2015/485065
   Web of Science ®Google Scholar
• Cagini C, Peruzzi C, Fiore T, Spadea L, Lippera M, Lippera S. Canaloplasty: current value in the management of glaucoma. J Ophthalmol. 2016;2016:7080475. doi:10.1155/2016/7080475
   Web of Science ®Google Scholar
• Arriola-Villalobos P, Martínez-de-la-Casa JM, Díaz-Valle D, et al. Mid-term evaluation of the new glaukos iStent with phacoemulsification in coexistent open-angle glaucoma or ocular hypertension and cataract. Br J Ophthalmol. 2013;97(10):1250–1255. doi:10.1136/bjophthalmol-2012-302394
   PubMed Web of Science ®Google Scholar
• Wang Q, Harasymowycz P. Short-term intraocular pressure elevations after combined phacoemulsification and implantation of two trabecular micro-bypass stents: prednisolone versus loteprednol. J Ophthalmol. 2015;2015:341450. doi:10.1155/2015/341450
   PubMed Web of Science ®Google Scholar
• McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33–55. doi:10.2165/00002018-200225010-00004
   PubMed Web of Science ®Google Scholar
• Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: A review of the literature. Eye. 2006;20(4):407–416. doi:10.1038/sj.eye.6701895
   PubMed Web of Science ®Google Scholar
• Dibas A, Yorio T. Glucocorticoid therapy and ocular hypertension. Eur J Pharmacol. 2016;787:57–71. doi:10.1016/j.ejphar.2016.06.018
   PubMed Web of Science ®Google Scholar
• Liu B, McNally S, Kilpatrick JI, Jarvis SP, O’Brien CJ. Aging and ocular tissue stiffness in glaucoma. Surv Ophthalmol. 2018;63(1):56–74. doi:10.1016/j.survophthal.2017.06.007
   PubMed Web of Science ®Google Scholar
• Wang K, Read AT, Sulchek T, Ethier CR. Trabecular meshwork stiffness in glaucoma. Exp Eye Res. 2017;158:3–12. doi:10.1016/j.exer.2016.07.011
   PubMed Web of Science ®Google Scholar
• Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol. 1963;70:492–499. doi:10.1001/archopht.1963.00960050494011
   PubMedGoogle Scholar
• Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013;2(2):55–72. doi:10.1007/s40123-013-0020-5
   PubMedGoogle Scholar
• Comstock TL, Sheppard JD. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opin Pharmacother. 2018;19(4):337–353. doi:10.1080/14656566.2018.1439920
   PubMed Web of Science ®Google Scholar
• Wu WM, Huang F, Lee Y, Buchwald P, Bodor N. Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats. J Pharm Pharmacol. 2008;60(3):291–297. doi:10.1211/jpp/60.10.0006
   PubMed Web of Science ®Google Scholar
• Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. J Ocul Pharmacol Ther. 1998;14(2):153–158. doi:10.1089/jop.1998.14.229
   PubMed Web of Science ®Google Scholar
• Bodor N, Loftsson T, Wu WM. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res. 1992;9(10):1275–1278. doi:10.1023/A:1015849132396
   PubMed Web of Science ®Google Scholar
• Rajpal RK, Roel L, Siou-Mermet R, Erb T. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2013;39(2):158–167. doi:10.1016/j.jcrs.2012.09.013
   PubMed Web of Science ®Google Scholar
• Fong R, Leitritz M, Siou-Mermet R, Erb T. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Clin Ophthalmol. 2012;6:1113–1124. doi:10.2147/OPTH.S32643
   PubMedGoogle Scholar
• Abessi B, Brooksby L, Schultze RL. Comparison of efficacy of difluprednate 0.05% and loteprednol gel 0.5% after cataract surgery. Eye Contact Lens. 2018;44(Suppl 2):S37–S42. doi:10.1097/ICL.0000000000000407
   Web of Science ®Google Scholar
• Salinger CL, Gordon M, Jackson MA, Perl T, Donnenfeld E. A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery. Clin Ophthalmol. 2015;9:2089–2097.
   PubMed Web of Science ®Google Scholar
• Mifflin MD, Betts BS, Frederick PA, et al. Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper. Clin Ophthalmol. 2017;11:1113–1118. doi:10.2147/OPTH.S138272
   PubMed Web of Science ®Google Scholar
• Price MO, Feng MT, Scanameo A, Price FW Jr. Loteprednol etabonate 0.5% gel vs. prednisolone acetate 1% solution after Descemet membrane endothelial keratoplasty: prospective randomized trial. Cornea. 2015;34(8):853–858. doi:10.1097/ICO.0000000000000475
   PubMed Web of Science ®Google Scholar
• Khaimi MA. A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty. Clin Ophthalmol. 2018;12:319–329. doi:10.2147/OPTH.S153912
   Web of Science ®Google Scholar
• Rebenitsch RL, Brown EN, Binder NR, et al. Effect of topical loteprednol on intraocular pressure after selective laser trabeculoplasty for open-angle glaucoma. Ophthalmol Ther. 2013;2(2):113–120. doi:10.1007/s40123-013-0018-z
   Google Scholar
• Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016;33(4):532–552. doi:10.1007/s12325-016-0315-8
   PubMed Web of Science ®Google Scholar
• Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 1993;9(2):157–165. doi:10.1089/jop.1993.9.157
   PubMedGoogle Scholar
• Holland EJ, Djalilian AR, Sanderson JP. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea. 2009;28(10):1139–1143. doi:10.1097/ICO.0b013e3181a2ad81
   PubMed Web of Science ®Google Scholar
• Coffey MJ, DeCory HH, Lane SS. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol. 2013;7:299–312.
   PubMedGoogle Scholar